2.77 USD
▲0.00+0.73%
盘后 2.70 -1.82%
2026-08-03
市值
$203.68M
市盈率
—
EPS
-0.67
股息率
—
52 周区间
2.48 – 5.48
成交量
21.23K
Beta
2.77
目标价
7.60
52W 低 2.4852W 高 5.48
价格走势
公司简介
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with...